{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:03:20Z","timestamp":1790809400322,"version":"4.1.0"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Spontaneous ocular haemorrhages under antithrombotic therapy are rare but can lead to persistent visual impairment up to blindness. Despite increasing prescriptions of antithrombotic medications, systematic overviews on incidence, risk factors, and management are lacking.<\/jats:p>\n                  <jats:p>Patients and Methods Based on a selective literature review, current clinical studies, registry data, and epidemiologic analyses on spontaneous ocular haemorrhages under oral\/parenteral anticoagulation and antiplatelet therapy were evaluated. The evidence was summarized regarding incidence, risk constellations, acute bleeding management, and therapy resumption.<\/jats:p>\n                  <jats:p>Results The risk of ocular haemorrhages varies significantly depending on medication, comorbidity, and combination therapy. Elderly patients with arterial hypertension, impaired renal function, and pre-existing eye diseases are particularly at risk. Dual antiplatelet therapy and combinations of anticoagulants and antiplatelet agents significantly increase the risk. Among oral anticoagulants, apixaban shows the most favourable ocular bleeding profile. Acute management strategies range from systemic reversal (e.g., idarucizumab, andexanet alfa) to ophthalmologic interventions (laser, vitrectomy). Therapy resumption should be coordinated interdisciplinarily.<\/jats:p>\n                  <jats:p>Conclusions Ocular haemorrhages under antithrombotic therapy require prompt, risk-adapted management. The choice of anticoagulant, control of modifiable risk factors, and clear decision algorithms for resumption of antithrombotic therapy are essential to prevent both vision loss and thromboembolic complications.<\/jats:p>","DOI":"10.1055\/a-2937-0560","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:15:36Z","timestamp":1786749336000},"source":"Crossref","is-referenced-by-count":0,"title":["Ocular haemorrhages under antithrombotic therapy: risk factors, management and clinical perspectives"],"prefix":"10.1055","author":[{"given":"Christoph","family":"Sucker","sequence":"additional","affiliation":[{"name":"Coagumed Gerinnungszentrum, Berlin, Deutschland, Germany","place":["Berlin"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zeitz","sequence":"additional","affiliation":[{"name":"Augentagesklinik Zehlendorf, Germany","place":["Berlin"]},{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin, Campus Benjamin Franklin, Augenklinik, Germany","place":["Berlin"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-3003","authenticated-orcid":false,"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsspital Basel Augenklinik, BS, Switzerland","place":["Basel"],"department":["Augenklinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10354-017-0577-z","volume":"168","author":"C Sucker","year":"2018","journal-title":"Wien Med Wochenschr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"A Holbrook","year":"2012","journal-title":"Chest"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"H-C Diener","year":"2004","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2015.0985","article-title":"Risk of substantial intraocular bleeding with novel Oral anticoagulants: systematic review and meta-analysis","volume":"133","author":"D Caldeira","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"j510","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"P B Nielsen","year":"2017","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"R D Lopes","year":"2012","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJMoa1002617","article-title":"Effect of home testing of international normalized ratio on clinical events","volume":"363","author":"D B Matchar","year":"2010","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"R Sarode","year":"2013","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.7861\/clinmedicine.18-4-314","article-title":"The reversal of anticoagulation in clinical practice","volume":"18","author":"S Thomas","year":"2018","journal-title":"Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3928\/23258160-20171215-04","article-title":"The prevalence of adverse ocular Hemorrhagic events in patients utilizing Oral anticoagulant and antiplatelet therapy in routine clinical practice","volume":"49","author":"D M Sudarshana","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/ijo.IJO_928_22","article-title":"Vitreous hemorrhage \u2013 causes, diagnosis, and management","volume":"71","author":"N Shaikh","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"J Hirsh","year":"2004","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"A GG Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants: new drugs and new concepts","volume":"7","author":"J H Levy","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archopht.1995.01100090070025","article-title":"Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19","volume":"113","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0039-6257(99)00036-3","article-title":"Vitrectomy in the management of diabetic retinopathy","volume":"43","author":"W E Smiddy","year":"1999","journal-title":"Surv Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"22139","DOI":"10.1038\/s41598-022-26289-6","article-title":"Displacement of submacular hemorrhage secondary to age-related macular degeneration with subretinal injection of air and tissue plasminogen activator","volume":"12","author":"M Ogata","year":"2022","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"J D Douketis","year":"2012","journal-title":"Chest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood-2009-02-207928","article-title":"Outcomes and predictors of very stable INR control during chronic anticoagulation therapy","volume":"114","author":"D M Witt","year":"2009","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"R M Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on Management of Bleeding in patients on Oral anticoagulants: a report of the American College of Cardiology Solution set Oversight Committee","volume":"76","author":"G F Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"M Levi","year":"2010","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2013 full cohort analysis","volume":"377","author":"C V Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"S J Connolly","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2937-0560.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:38:46Z","timestamp":1790807926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2937-0560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1055\/a-2937-0560","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,14]]},"published":{"date-parts":[[2026,8,14]]}}}